Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-23T05:34:01.421Z Has data issue: false hasContentIssue false
  • English
  • Français

Presumed reduction of vestibular function in unilateral Menière's disease with aminoglycoside eardrops

Published online by Cambridge University Press:  29 June 2007

Andrew P. Bath ,
Rory M. Walsh  and
Manohar L. Bance
Andrew P. Bath
Affiliation:
Department of Otolaryngology, The Toronto Hospital, Toronto, Ontario, Canada
Rory M. Walsh
Affiliation:
Department of Otolaryngology, The Toronto Hospital, Toronto, Ontario, Canada
Manohar L. Bance*
Affiliation:
Department of Otolaryngology, The Toronto Hospital, Toronto, Ontario, Canada
*
Address for correspondence: Dr M. Bance, Department of Otolaryngology, The Toronto Hospital, General Division, EN7-221, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada. Fax: (416) 340 5116
Get access Rights & Permissions [Opens in a new window]

Abstract

We report the first case in the world literature of deliberate ablation of vestibular function in unilateral Meniere's disease with aminoglycoside eardrops (Garasone).

These findings give conclusive proof that Garasone eardrops, and by implication, all topical aminoglycoside ear drops can be vestibulotoxic in the presence of a tympanic membrane defect. The lower concentration of gentamicin in Garasone, in comparison to the standard intratympanic preparations for chemical ablation of vestibular function, may also offer a reduction in the potential risk of cochleotoxocity.

Keywords

AminoglycosidesMenière's diseaseVertigoDisease management
Type
Clinical Records
Information
The Journal of Laryngology & Otology , Volume 113 , Issue 10 , October 1999 , pp. 916 - 918
Copyright
Copyright © JLO (1984) Limited 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Beck, C., Schmidt, C. L. (1978) Ten years of experience with intratympanically applied streptomycin (gentamicin) in the therapy of Morbus Meniere. Archives of Otolaryngology 221: 149–152.Google Scholar
Driscoll, C. L. W., Kasperbauer, J. L., Facer, G. W., Harner, S. G., Beatty, C. W. (1997) Low-dose intratympanic gentamicin and the treatment of Meniere's disease: preliminary results. Laryngoscope 107: 83–89.CrossRefGoogle ScholarPubMed
Goycoolea, M. V., Muchow, D., Schachern, P. (1988) Experimental studies on round window structure: function and permeability. Laryngoscope 98 (Suppl): 1–20.CrossRefGoogle ScholarPubMed
Hui, Y., Park, A., Crysdale, W. S., Forte, V. (1997) Ototoxicity from ototopical aminoglycosides. Journal of Otolaryngology 26: 53–56.Google ScholarPubMed
Kwabata, I., Paparella, M. M. (1971) Fine structure of the round window membrane. Annals of Otology, Rhinology and Laryngology 80: 13–27.CrossRefGoogle Scholar
Lange, G. (1989) Gentamicin and other ototoxic antibiotics for the transtympanic treatment for Meniere's disease. Archives of Otorhinolaryngology 246: 269–270.CrossRefGoogle ScholarPubMed
Lind, O., Kristiansen, B. (1986) Deafness after treatment with ear drops containing neomycin, gramicidin and dexamethasone. Otorhinolaryngology 48: 52–54.Google ScholarPubMed
Longridge, N. S. (1994) Topical gentamicin vestibular toxicity. Journal of Otolaryngology 23: 444–446.Google ScholarPubMed
Marais, J., Rutka, J. A. (1998) Ototoxicity and topical eardrops. Clinical Otolaryngology 23: 360–367.CrossRefGoogle ScholarPubMed
Moller, C., Odkvist, L. M., Thell, J., Larsby, B., Hyden, D. (1988) Vestibular and audiologic functions in gentamicin treated Meniere's disease. American Journal of Otology 9: 383–391.Google ScholarPubMed
Nedzelski, J. M., Chiong, C. M., Fradet, G., Schessel, D. A., Bryce, G. E., Pfleiderer, A. G. (1993) Intratympanic gentamicin instillation as treatment of unilateral Meniere's disease: update of an ongoing study. American Journal of Otology 14: 278–282.Google ScholarPubMed
Podoshin, L., Fradis, M., David, J. B. (1989) Ototoxicity of ear drops in patients suffering from chronic otitis media. Journal of Laryngology and Otology 103: 46–50.CrossRefGoogle ScholarPubMed
Rauch, S. D., Oas, J. G. (1997) Intratympanic gentamicin for treatment of intractable Meniere's disease: a preliminary report. Laryngoscope 107: 49–55.CrossRefGoogle ScholarPubMed
Schuknecht, H. F. (1957) Ablation therapy in the management of Meniere's disease. Acta Otolaryngologica (Stockholm) 132: 1–42.Google ScholarPubMed
Tommerkup, B., Moller, K. (1984) A case of profound hearing impairment following the use of Framycetin ear drops. Journal of Laryngology and Otology 98: 1135–1137.CrossRefGoogle Scholar
Tran, Ba Huy P., Meulemans, A., Wassef, M., Manuel, G., Sterkers, O., Amiel, C. (1983) Gentamicin persistence in rat endolymph and perilymph after two-day constant infusion. Antimicrobial Agents and Chemotherapy 23: 334–346.Google Scholar
Wong, D. L. H., Rutka, J. A. (1997) Do aminoglycoside otic preparations cause ototoxicity in the presence of tympanic membrane perforations? Otolaryngology – Head and Neck Surgery 116: 404–410.CrossRefGoogle ScholarPubMed
Yamazaki, T., Hayashi, M., Komatsuzaki, A. (1991) Intra-tympanic gentamicin therapy for Meniere's disease placed by a tubal catheter with systemic isosorbide. Acta Otolaryngologica Supplement (Stockholm) 481: 613–616.CrossRefGoogle Scholar